OCSOculis Holding AG
Price
-63%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 3% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for OCS today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
Switzerland, the U.S. and Iceland. We have substantial expertise in therapeutics for the treatment of neuro-ophthalmic and ophthalmic diseases. We are engaged in developing innovative drug candidates that embrace the potential to address significant unmet medical needs. We intend to become a global leader in neuro-ophthalmic and ophthalmic therapeutics to realize this mission. Our pipeline currently includes three clinical-stage therapeutic candidates: OCS-01, Licaminlimab (OCS-02) and Privosegtor (OCS-05).
In the company’s own words · 20-F filed Mar 4, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Oculis Holding AG (OCS) reported revenue of CHF 654K in H2 2025 (quarter ended Dec 31, 2025), up 167% from the same quarter a year earlier. That came with net loss of CHF 40M. For the full year FY2025, revenue was CHF 1.2M (+75% year on year) and net income −CHF 99M.